Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - PDS Biotechnology Corp | nc10023834x3_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - PDS Biotechnology Corp | nc10023834x3_ex99-1.htm |
| 8-K - FORM 8-K - PDS Biotechnology Corp | nc10023834x3_8k.htm |
Exhibit 99.3
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO MAY 2021
2 Forward-Looking Statements This presentation contains forward-looking statements about PDS
Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market
opportunities. All statements other than statements of historical facts included in this presentation are forward-looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,”
“likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward-looking statements. These forward-looking statements involve substantial risks and
uncertainties that could cause actual results to differ materially from those anticipated.Factors that may cause actual results to differ materially from such forward-looking statements include those identified under the caption “Risk
Factors” in the documents filed with the Securities and Exchange Commission from time to time, including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this presentation. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included
in this presentation to reflect subsequent events or circumstances.
3 PDS Biotech’s Versamune®-based immunotherapies promote a powerful in vivo tumor-specific CD8+
killer T-cell response Generate a strong CD8+ T-cell memory response resulting in long-lasting efficacy Are versatile and shown to be effective on their own or in combination with other drugs to improve their efficacy Generate potency
without systemic side effects The most significant barrier to effective immunotherapy has been their inability to promote adequate CD8+ killer T-cell responses in vivo resulting in diminished efficacy Versamune®-based therapies also:
PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on
the proprietary Versamune® platform 4 NCI-initiated phase 2 HPV-cancer trial surpassed initial efficacy requirement prompting expansion to full enrollmentNovel COVID-19 vaccine candidate being developed in Brazil with consortium
partnersMCTI, Brazil to fund COVID-19 vaccine manufacturing scale up and clinical trialsPre-clinical studies demonstrated potential to work with a wide array of oncogenes and viral antigensMultiple composition and application patents valid
through mid-2030s Biopharma developing novel cancer treatment candidates and T-cell-activating vaccine candidates for infectious diseasesThree phase 2 oncology clinical trials in progress to initial data releases in 2021Clinical partnerships
with Merck, MD Anderson and National Cancer Institute~15 employees with headquarters in Florham Park, NJDebt free with approximately $25.0M in cash as of 3/31/21 Pipeline Versamune® Platform Corporate Overview
PDS Biotech’s robust Versamune®-based pipeline is being developed in partnership with the leaders in
immuno-oncology and infectious disease 5 Reference: Data on file. * *Consortium of PDS Biotech, Farmacore and Blanver. Funding provided by The Ministry of Science, Technology and Innovation of Brazil (MCTI)
PDS Biotech executive team has demonstrated success in the development and commercialization of leading
pharmaceutical products 6 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet® (Liposome Company/ Elan)PEG-Intron® (Schering-Plough/ Merck) Frank
Bedu-Addo, PhDChief Executive Officer Co-founder>35 years of drug development experience In-depth experience with biotech drug discovery, product development and manufacturing Gregory Conn, PhDChief Scientific Officer >30 years
of translational clinical research experienceFormer Director of Clinical Research at National Cancer Institute Center for Cancer Research (Cancer Vaccine Branch) Lauren V. Wood, MDChief Medical Officer Senior executive experience with
over 20 years of experience in high tech companiesIn-depth experience with M&A transactions, capital markets, business development and investor relations Seth Van Voorhees, PhDChief Financial Officer
Introduction to the Versamune® Platform
Versamune® is designed to induce a robust and targeted anti-tumor response in vivo when administered
with a tumor-associated antigen 8 Reference: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol.
202 (12): 3524-3536.Smalley Rumfield C et al.. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612. Promotes uptake of vaccine or immunotherapy and entry into lymph
nodes Promotes antigen processing and presentation to T-cells via MHC I and II pathways Activates Type I Interferon pathway, enabling a powerful anti-tumor killer CD8+ T-cell response Versamune® + Tumor-associated proteins (antigens)
Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to
eradicate HPV-positive tumors after a single dose 9 Induced a >10-fold number of highly potent T-cells and eradication of HPV-positive tumors after a single dose in preclinical studies Single treatment dose Results typical of current
topclinical-stage HPV cancer vaccines Tumor rechallenge at Day 60; complete and sustained cure of cancer *Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202), 1215; Studies in TC-1 tumor model with other immunotherapies
reported in: Vaccine 2009, January 14, 27 (3): 431; Science Translational Medicine 2016, 13 April, Vol 8 Issue 334; Vaccine 2009, September 25, 27 (42): 5906. (PDS0101)
PDS0101 Phase 2 Clinical Development
Combinations of PDS0101 with FDA-approved standard of careFirst line treatment of recurrent/metastatic
HPV-positive head and neck cancerCombination with Keytruda®Treatment of advanced localized cervical cancerCombination with chemoradiotherapy 11 Novel combinations of PDS0101 with promising, investigational immunotherapeutic agentsTreatment
of advanced HPV-associated cancers (anal, cervical, vaginal, head and neck etc.)Triple combination with Bintrafusp-alpha (bi-functional checkpoint inhibitor - M7824) and M9241 (antibody conjugated immuno-cytokine) Clinical strategy: Develop
PDS0101 in combination with established therapies for rapid proof-of-concept and risk mitigation
Phase 2 investigator-led clinical trial evaluating the combination of PDS0101, M7824 and NHS-IL12 in
advanced HPV-associated cancer 12 Indication Patients with advanced HPV-associated cancer who have failed prior treatment Clinical Agents Bintrafusp alfa (M7824): Bifunctional “trap” fusion proteinM9241 (NHS-IL12): Antibody-conjugated
immuno-cytokinePDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ T-cells Study goals Group 1: Objective response rate (ORR) in checkpoint inhibitor (CPI) naïve patientsGroup 2: ORR in patients who have failed checkpoint
inhibitor therapy (CPI refractory) Timing Full enrollment of 45 patients triggered following achievement of objective response in ≥ 3 checkpoint inhibitor naive patientsTrial completion expected in Q1 2022 Trial Sponsor The objective of
this trial is to confirm that PDS0101 enhances the therapeutic benefit of M7824 & NHS IL-12 and may lead to expanded evaluation in several cancers with PDS0102-0104
13 Bintrafusp alfa (bi-functional checkpoint inhibitor)+ M9241 (immuno-cytokine (NHS-IL12)) Tumor
Regression: 8/16 (50%)T-cell Clones: 18 PDS0101 + Bintrafusp alfa + M9241 Tumor Regression: 13/17 (76%)T-cell Clones: 3 *Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of Cancer 2020; 8:e000612.
doi: 10.1136/jitc-2020-000612 In a preclinical model, PDS0101 demonstrated enhanced ability to train tumor-specific T-cells to be effective in infiltrating and killing tumors Red – CD8+ (killer) T-cellsGreen – CD4 + (helper)
T-cells T-cell clones per 25% of TCR repertoire (Average) Combination of PDS0101 with M9241 or Bintrafusp alfa (M7824) generated superior targeted T-cell response; triple combination demonstrated superior efficacy
PDS0101 Phase 1 clinical trial: Powerful CD8+ T-cell response resulted in regression of CIN cervical
lesions & supported continued clinical studies 14 * When treated with selected human clinical trial dosage (1mg and 3mg Versamune®)References: L. Wood et al. A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens
Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papillomavirus Infection. Nov 8, 2019. SITC. Presentation O17. Most patients infected with multiple strains of HPV CIN lesion regression
at 1-3 months 60% 20% 20% Phase 1 trial results showed no serious or dose-limiting toxicities of PDS0101 monotherapy Monotherapy overcomes key limitation of immuno-oncology: > 20-fold increase in circulating dual INF-γ &
Granzyme-b inducing killer T-cells vs. pre-treatment at day 14 led to rapid clearance of lesions*
Triple combination of PDS0101, Binstrafusp alfa and M9241 works synergistically to induce targeted
T-cells to attack and infiltrate the tumor 15 Bintrafusp alfa exposes the tumor to attack and M9241 issues a signal calling T-cells to the tumor Reference: Smalley Rumfield C, Pellom ST, Morillon II YM, et al; Journal for ImmunoTherapy of
Cancer 2020; 8:e000612. doi: 10.1136/jitc-2020-000612 BINTRAFUSP ALFA M9241 PDS0101 induces a powerful, HPV16-targeted CD8+ and CD4+ T-cell response PDS0101 Activated CD8+ killer T-cell Activated CD4+ helper
T-cell The triple combination works in synergy to prompt targeted T-cells to infiltrate and destroy the tumor TUMOR DESTROYED
Objective response rate is measured by RESCIST 1.1 and represents at least a 30% reduction in tumor
sizeAdvanced recurrent/refractory HPV-related cancer that is checkpoint inhibitor naïve:Patients who fail chemotherapy and/or radiation progress to checkpoint inhibitor therapy12-24% ORR with standard of care checkpoint inhibitors30% ORR
reported by experimental therapy Bintrafusp alfa is the highest reported to dateAdvanced recurrent/refractory HPV-related cancer that is checkpoint inhibitor refractory:Few treatment options exist for these patients5-10% ORR reported with
checkpoint inhibitors PDS0101 phase 2 triple combination trial: Evaluated potential for superior preclinical tumor regression in advanced HPV-related cancer 16 The most critical limitation of immunotherapy is the inability to induce large
numbers of powerful tumor-attacking CD8+ (killer) T-cells within the body, that can result in tumor reduction or elimination in a significant number of advanced cancer patients Strauss J, et al. J Immunother Cancer. 2020 Dec;8(2):e001395
Checkpoint inhibitor naïve patients (Relapsed or refractory advanced cancer)Tumor types represented in
checkpoint inhibitor naïve study arm include anal, cervical, head and neck and vaginal Triple combination achieved 83% ORR among 6 HPV16-positive patients 17 HPV16 positive subjects CurrentStandard of Care(Checkpoint Inhibitors) Number
of subjects 6 Number of objective responses (tumor reduction) 5 Percentage of objective responses 83% 12-24% Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in
patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 14 patients; numbers will change
as more patients undergo evaluation Preliminary results suggest PDS0101 induction of in-vivo tumor-attacking HPV16 killer (CD8+) T-cells may result in effective targeting of the HPV16-positive tumors resulting in disease reduction
Checkpoint inhibitor refractory patientsTumor types represented in checkpoint inhibitor naïve study arm
include anal, cervical, head and neck and vulvar Preliminary results suggest the triple combination may provide superior efficacy over checkpoint inhibitor monotherapy, even in immunologically limited patients Triple combination achieved
63% ORR among 8 HPV16-positive checkpoint inhibitor refractory patients 18 HPV16 positive subjects Current Standard of Care Number of subjects 8 Number of objective responses (tumor reduction) 5 Percentage of objective
responses 63% 5-12% Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021
Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501. * These numbers reflect data as of evaluation of 14 patients; numbers will change as more patients undergo evaluation
19 PDS Biotech-sponsored phase 2 trial evaluating the combination of PDS0101 and KEYTRUDA for
first-line treatment of HPV-associated metastatic/recurrent head and neck cancer Indication First line treatment of patients with HPV-associated head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA (Standard
of Care): Anti-PD1 checkpoint inhibitor (ORR ~20%)PDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Objective response rate (ORR) and overall survival (OS) Timing Preliminary data – Q4
2021/Q1 2022, ORR in first 20 patients (efficacy in 7 of 38 required to enroll all 96 patients) Trial Partner If achieved, confirmation that PDS0101 enhances the therapeutic benefit of checkpoint inhibitors could expand evaluation of
Versamune®-based therapies in multiple cancer indications
20 A Phase 2, investigator-initiated clinical trial evaluating PDS0101 in combination with
chemoradiation therapy in patients with advanced cervical cancer Indication Treatment of patients with locally advanced cervical cancer – Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT – Standard of Care): Cisplatin & radiation
therapyPDS0101: Versamune®-based immunotherapy generating HPV-specific CD8+ and CD4+ T-cells Study goals Rate of regression in patients with primary tumor ≥5cm Timing Preliminary data – Q4 2021/Q1 2022 – Rate of complete response by
PET-CT at 6 months and rate of tumor volume reduction by MRI at 30-40 days from start of treatment Trial Sponsor If successful, this study could support further investigation of Versamune®-based immunotherapies in combination with
chemotherapy or CRT to treat multiple cancers
Studies are designed to demonstrate efficacy and broad applicability of PDS0101 and the Versamune®
T-cell activating platform 21 Potential to enhance anti-cancer efficacy of various cancer treatments: Combinations with checkpoint inhibitors, chemotherapy and novel therapies may demonstrate Versamune®’s versatility. Broad potential for
additional partnerships: Successful phase 2 studies with PDS0101 and PDS0203 could enable a broad pipeline of Versamune®-based products containing various antigens. Potential to treat all types of HPV-cancer: PDS0101 Phase 2 clinical studies
address all types of HPV-associated cancers. Potential applications beyond oncology: PDS0203 COVID-19 phase 1/2 trials may demonstrate protection and induce durable T-cell responses against conserved regions of mutating viruses.
PDS0203 Phase 1/2 Clinical Development
Mt. Sinai data shows Versamune® promotes induction of neutralizing antibodies with lowest doses of
SARS-CoV-2 antigen1 23 1Reference: Sun et al. 2020. Vaccines Volume 8, Issue 42Reference: Data on file PDS Biotech preclinical data shows induction of SARS-CoV-2 specific CD8+ T-cells with Versamune®2 Preclinical studies show potentially
powerful induction of long-lasting polyfunctional CD8+ and CD4+ anti-SARS-CoV-2 T-cells Developing a Versamune®-based COVID-19 vaccine candidate with the goal of promoting CD8+ T-cell responses and neutralizing antibodies
Development of PDS0203, if successful, may offer potential advantages as a second generation COVID-19
vaccine May be effective against multiple COVID-19 variantsDemonstrated induction of killer CD8+ and helper CD4+ T cells that can target less variable regions of the SARS-CoV-19 virus and may be effective against currently circulating
variants.May grant long-lasting immunityDemonstrated induction of long-lasting, virus-specific memory T-cells necessary for longer term protection.High potential for safetyPDS0203 is a subunit vaccine, and does not require the use of
attenuated viruses, traditional adjuvants, DNA or RNA. Versamune®-based vaccines have shown no serious or dose limiting reactions. 24
Looking Forward
26 Approximately 43,000 patients are diagnosed with HPV-associated cancers annually in the USIncidence
rate is growing despite increased use of HPV preventative vaccinesSignificant unmet medical need across the spectrum of HPV-associated cancerExisting immunotherapies cost $120,000+ annually per patient2 1Markowitz et al. 2016. Centers for
Disease Control and Prevention. 2018.2Hernandez et al. 2018. American Journal of Managed Care Volume 24, Issue 2; Company Research Females (24,391) Males (18,280) US annual HPV-associated cancer incidence1 PDS0101 is designed to treat
cancers caused by human papillomavirus (HPV)
Consortium has received a commitment of up to ~US$60 million from MCTI, Brazil to support phase 1-3
clinical development and manufacturing scale-upPhase 1/2 study anticipated to start in Q2/Q3 of 2021 pending approval from Anvisa, Brazilian regulatory agencyPending results and regulatory procedures, PDS0203 could be commercially available
in Brazil in 2023Initial target market – Latin America ~ 650 million people (Brazil ~213 million people)1Based on public information, COVID-19 vaccine prices range from $20-74 for a two-dose regimen2 PDS0203, if development is successful,
could offer another option to address the COVID-19 global health crisis 1The World Population Review. 2021.2Comparing COVID-19 Vaccines: Timelines, Types and Prices, BioSpace, 2/8/21; Company Research 27
Projected milestones through 2022* *Based on current enrollment and forecast modeling as of April
2021. Subject to change.**Consortium funding provided by MCTI, Brazil 4Q22 3Q22 2Q22 1Q22 4Q21 3Q21 2Q21 1Q21 Preliminary efficacy Data from advanced HPV-associated cancer trial (NCI) Interim Data from HPV-associated Cancer trial
(NCI) expected Preliminary Data from ImmunoCerv combo trial (MD Anderson) expected Potential interim data from VERSATILE-002 (Keytruda combo) Initiation of Phase 1/2 COVID clinical trial of PDS0203 Initiation of Phase 3 COVID clinical
trial of PDS0203 Efficacy data from Phase 3 COVID clinical trial of PDS0203 Completion of HPV-associated cancer trial (NCI) PDS0101 PDS0203** 28 PDS Biotech Funded Clinical Trials Partner Co-Funded Clinical Trials
Versamune® has demonstrated the potential for immunological compatibility with a wide array of tumor
and pathogenic antigens Reference: Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737 We believe that Versamune®’s unique flexibility means it may work well with a wide range of identified tumor and infectious
disease antigensToday, 4 tumor antigens are being utilized with the Versamune® platform, more than 75 tumor antigens have been identified in oncologyToday, 3 infectious disease antigens are being developed with the Versamune® platform, more
than 12 infectious disease antigens have been identified as potential targetsProof of concept data from ongoing clinical trials could trigger development activities for Versamune®-based products through partnerships and licensing 29
Rapid commercialization strategy 30 Promising early data in both oncology and infectious disease:
Early clinical data and preclinical data suggest potential efficacy, safety and versatility of the Versamune® platformNear-term milestones: PDS0101 preliminary efficacy data anticipated in Q2 2021 and PDS0203 safety and immunogenicity data
projected in Q4 2021/Q1 2022Validation of approach: All three on-going phase 2 clinical trials supported and partnered with leading and top-tier institutions in the field of cancer and immuno-oncologyCommercialization path: Anticipated
commercialization of PDS0203 in Brazil in 2023 and clinical studies demonstrating enhancement of FDA-approved anti-cancer products may offer potential for expedited programsRapid adoption strategy: Evaluation of PDS0101 in combination with
standard of care in multiple HPV-associated cancers Potential Advantages and Differentiators
